WO2004071515A1 - Preparation de derives de monosaccharide - Google Patents
Preparation de derives de monosaccharide Download PDFInfo
- Publication number
- WO2004071515A1 WO2004071515A1 PCT/IB2003/000471 IB0300471W WO2004071515A1 WO 2004071515 A1 WO2004071515 A1 WO 2004071515A1 IB 0300471 W IB0300471 W IB 0300471W WO 2004071515 A1 WO2004071515 A1 WO 2004071515A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- group
- carried out
- disorder
- Prior art date
Links
- 0 C[N+](C(C(C1O*OC11)OC1O*)*=C)=O Chemical compound C[N+](C(C(C1O*OC11)OC1O*)*=C)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
Definitions
- the present invention relates to an improved and industrially advantageous process for the preparation of derivatives of monosaccharides. More particularly, derivatives corresponding to compounds of Formula I.
- CAM's cell adhesion molecules
- CAM's cell adhesion molecules
- CAM's cell adhesion molecules
- CAM's have been demonstrated to participate in various cell-cell, cell-extracellular matrix, and platelet- platelet interactions.
- CAM's influence the leukocytes, adhesion to the vascular endothelium, their transendothelial migration, retention at extravascular sites, and activation of T cells and eosinophils. These processes are central to the pathogenesis of inflammatory and autoimmune diseases. Therefore, CAM's are considered potential targets in treating such disorders.
- CAM's can be classified into three groups: integrins, selectins and the immunoglobulins superfamily. Of these, integrins are key mediators in the adhesive interactions between hemopoietic cells, and other components in their microenvironments. Integrins can be classified on the basis of beta subunits they contain.
- the alpha - 4 beta — 1 integrin also known as NLA (very late activation antigen 4), is a member of the beta - 1 integrin family and comprises alpha - 4 and beta - 1 subunits.
- NLA interacts with two specific ligands: the vascular cell adhesion molecule (NC AM- 1 ) and the CS 1 region of fibronectin.
- Adhesion mediated by NLA is central to the process of transendothelial migration of leukocytes. Ligation of NLA 4 is followed by gross rearrangement of the cytoskeleton, leading to flattening of cells along the blood vessel wall, followed by expression of specific molecules that digest the endothelial cell wall diapedesis.
- NLA 4 . With extracellular fibronectin play a crucial role in the migration of leukocytes to the site of inflammation, T cell proliferation and expression of cytokines and inflammatory mediators. Additionally, NLA 4 . ligation provides co-stimulatory signals to the leukocytes, resulting in enhanced immunoreactivity. Thus, appropriate N A antogonists would, in theory, ameliorate the immune response through a two fold action inhibition of T cell recruitment at the site of inflammation and inhibition of co-stimulatory activation of immune cells.
- compounds of Formula I are useful for, inter alia, the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection and psoriasis.
- United States Patent No. 6,329,344 also discloses the synthesis of compounds of Formula I
- R is C1 to C15 alkyl, alkene, straight chain alkyne or branched alkyne, aryl, substituted aryl or alkylaryl;
- R is SO2C6H5, SO2C6H .CH3-P., or SO2C6H4CI-P, phenyl or substituted phenyl, represented as C 6 H 4 -R"'-p wherein R'" is CI, NO 2 , OCH3, CH3, CH 2 COOH,
- R" is H or CH 3; which comprises reacting 2,3-O-isopropylidine-6-deoxy-l-O-alkyl, alkene, alkyne (straight chain or branched), aryl, substituted aryl or alkylaryl mai ofuranoside of Formula II
- the present invention is directed to solving the problems associated with processes for the preparation of compounds of Formula I described in the prior art and to providing an efficient process for the preparation of compounds of Formula I. Benefits with respect to economics, safety, and convenience in commercial scale operations are offered.
- the present invention relates to processes for the syntheses of compounds of Formula I
- R is C to C15 alkyl, alkene, straight chain alkyne or branched alkyne, aryl, substituted aryl or alkylaryl;
- R * is SO2C6H5, SO2C6H4CH3-p i or SO2C6H4CI-P, phenyl or substituted phenyl, represented as C6H 4 -R"'-p wherein R'" is CI, NO 2 , OCH3, CH3, CH 2 COOH, CH 2 COOCH 3 , CH 2 COLDNP, CH 2 CODNP, CH 2 CONP wherein LDNP, DNP and NP represent tetrapeptide (Leucyl-aspartyl-valyl-prolyl), tripeptide (aspartyl-valyl-prolyl) and dipeptide (valyl-prolyl), respectively (alternate terra-, hi- and dipeptides containing amino acids which are equivalent to those described can also be used);
- R" is H or CH 3 , which comprises, reacting a compound of Formula II
- R and R" are the same as defined above, with a leaving group, for example, methanesulphonyl chloride, in an organic solvent such as nonpolar, aprotic solvents, including dichloromethane, dichloroethane, chloroform, tetrahydrofuran or acetone, in presence of an organic base, such as triethylamine, triethylamine, ⁇ -methyl morpholine or isopropylamine, and the reaction mixture is allowed to stir for about 30 minutes to yield the organic compound of Formula IN
- this compound of Formula-N is further treated with palladium-carbon in presence of an acid such as formic acid or acetic acid in an alcohol such as methanol or ethanol to yield the compound of Formula III
- L represents a leaving group such as alkoxy, aryloxy or arylalkoxy
- R is the same as defined above in an organic solvent such as dichloromethane, dichloroethane, chloroform, tetrahydrofuran and acetone in presence of an organic base such as triethylamine, ⁇ -methyl morpholine and isopropylamine to yield the compound of Formula I
- Particular compounds synthesized according to the invention and capable of being produced by the above mentioned process include: l-O-dodecyl-2,3-O-isopropylidene-5,6-dideoxy-5- ⁇ -[4-(2-methoxy-2- oxoethyl)phenylamino carbonyl]amino- ⁇ ,L-gulofuranoside.
- the compounds of Formula I prepared by the processes disclosed herein can be used to make up pharmaceutical compositions. Such compositions can be formulated into solid dosage forms for oral administration, such as, for example, tablets, granules, capsules, pills, and the like.
- the medicaments can be prepared by conventional methods, including a therapeutically effective amount of a compound of Formula I, and pharmaceutically acceptable excipients.
- the administration of pharmaceutical compositions can be by injection or by gradual infusion over time.
- the compositions can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
- Preferred methods for delivery of the compositions include orally, by encapsulation in microspheres or proteinoids, by aerosol delivery to the lungs, or transdermally by iontophoresis or transdermal electroporation. Other methods of administration will be known to those skilled in the art.
- the compositions may also be administered by controlled release means and/or delivery devices, with modifications known to those of ordinary skill in the art.
- compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- terapéuticaally effective amount is meant the quantity of a compound or composition according to the invention necessary to prevent, cure or at least partially arrest the symptoms of the disorder and its complications.
- cell adhesion inhibiting amounts or cell adhesion preventing amounts are the amounts of compound or composition necessary to inhibit or prevent cell adhesion. Amounts effective to achieve this goal will, of course, depend on the severity of the disease and the weight and general state of the patient. Methods of Treatment
- compositions provided herein can be utilized for various treatment methods, such as those for treating inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, and psoriasis.
- inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type-I diabetes, multiple sclerosis, allograft rejection, and psoriasis.
- the methods include administering to a mammal a therapeutically effective amount of a pharmaceutical composition as described herein.
- a pharmaceutical composition as described herein.
- the administration of pharmaceutical compositions can be by oral or buccal administration,. Other methods of administration will be known to those skilled in the art.
- Example 1 Preparation of l-O-dodecyl-2,3-O-isopropyridene— 5, 6-dideoxy-5-N-
- Benzylamine (2.16 kg, 20.18 moles, 8.27 equivalents) was added in one lot to 1- O-dodecyl-2, 3-0 -isopropylidene-6-deoxy-5-O-methanesulphonyl- ⁇ , D- mamiofuranoside (1.1 kg, 2.44 moles) and the mixture was stirred at 120° C for 5 - 6 hours. The progress of the reaction was monitored by TLC (30% ethyl acetate in hexane). After completion of the reaction, benzylamine was removed by distillation under vacuum and the reaction mixture was cooled to 50 - 60°C. Hexane (2.75 L) was added and cooled to room temperature.
- Step 3 Preparation of l-O-dodecyI-2, 3-O-isopropylidene-5, 6-dideoxy-5-amino- ⁇ , L-gulofuranoside
- Step 4 Preparation of l-O-dodecyl-2,3-O-isopropylidene-5, 6-dideoxy-5-N-[4-(2- methoxy -2-oxoethyl)phenyIaminocarbonyl]amino- ⁇ , L-gulofuranoside
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2003/000471 WO2004071515A1 (fr) | 2003-02-12 | 2003-02-12 | Preparation de derives de monosaccharide |
AU2003202767A AU2003202767A1 (en) | 2003-02-12 | 2003-02-12 | Preparation of monosaccharide derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2003/000471 WO2004071515A1 (fr) | 2003-02-12 | 2003-02-12 | Preparation de derives de monosaccharide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004071515A1 true WO2004071515A1 (fr) | 2004-08-26 |
Family
ID=32865982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/000471 WO2004071515A1 (fr) | 2003-02-12 | 2003-02-12 | Preparation de derives de monosaccharide |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003202767A1 (fr) |
WO (1) | WO2004071515A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092907A2 (fr) * | 2004-03-26 | 2005-10-06 | Ranbaxy Laboratories Limited | Derives de monosaccharide |
WO2005100373A2 (fr) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | Derives du monosaccharide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329344B1 (en) * | 1998-10-22 | 2001-12-11 | Ranbaxy Laboratories Limited | Derivatives of monosaccharides as cell adhesion inhibitors |
-
2003
- 2003-02-12 WO PCT/IB2003/000471 patent/WO2004071515A1/fr not_active Application Discontinuation
- 2003-02-12 AU AU2003202767A patent/AU2003202767A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329344B1 (en) * | 1998-10-22 | 2001-12-11 | Ranbaxy Laboratories Limited | Derivatives of monosaccharides as cell adhesion inhibitors |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005092907A2 (fr) * | 2004-03-26 | 2005-10-06 | Ranbaxy Laboratories Limited | Derives de monosaccharide |
WO2005092907A3 (fr) * | 2004-03-26 | 2006-04-27 | Ranbaxy Lab Ltd | Derives de monosaccharide |
WO2005100373A2 (fr) * | 2004-04-13 | 2005-10-27 | Ranbaxy Laboratories Limited | Derives du monosaccharide |
WO2005100373A3 (fr) * | 2004-04-13 | 2006-04-06 | Ranbaxy Lab Ltd | Derives du monosaccharide |
Also Published As
Publication number | Publication date |
---|---|
AU2003202767A1 (en) | 2004-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0917462B1 (fr) | Inhibiteurs d'adhesion cellulaire | |
WO2004106343A2 (fr) | Molecules et analogues de la famille agelastatine d'alkaloides antitumuraux et inhibiteurs de gsk-3? | |
TR201816146T4 (tr) | Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem. | |
EP1144425B1 (fr) | Derives de monosaccharides en tant qu'inhibiteurs de l'adhesion cellulaire | |
SI9620099A (sl) | Diglikozilirani 1,2-dioli kot mimetiki sialil-Lewis X in sialil-Lewis A | |
EP0340064A1 (fr) | Benzodiazépines, leur procédé et intermédiaires de préparation et leurs applications en thérapeutique | |
WO2005077902A2 (fr) | Methodes de synthese de pyridoxamine | |
AU768511B2 (en) | 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors | |
WO2004071515A1 (fr) | Preparation de derives de monosaccharide | |
CN112047915B (zh) | C-糖苷类衍生物新的制备工艺 | |
JPS63303991A (ja) | エピポドフイロトキシングルコシドの窒素含有誘導体 | |
SE443784B (sv) | Nya foreningar med farmakologisk verkan | |
FR2927076A1 (fr) | Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent | |
JPH0662591B2 (ja) | 新規なチオプロリン誘導体 | |
KR870000312B1 (ko) | 6-(알콕시아미노메틸) 페니실란산 1,1-디옥사이드 및 그의 유도체의 제조방법 | |
US20030236397A1 (en) | Process for preparing beta-L-2'deoxy-thymidine | |
US4251515A (en) | Novel nitrosourea derivatives | |
EP0240986A2 (fr) | Dérivés de D-Nor-7-ergoline, procédé pour leur préparation, composition pharmaceutique et utilisation | |
FR2487359A1 (fr) | 11a-amino-androstanes, leur preparation et compositions en contenant | |
US3919191A (en) | 14,15{62 -Epoxycardenolide- and 14,15{62 -epoxybufadienolide-glycosides and process for their preparation | |
WO2004099229A1 (fr) | Procede de synthese des sels d'addition de base de 5,6-dideoxy-5-n-(4-(2-hydroxy-2-oxoethyl)-phenylaminocarbonyl) amino-l-gulofuranosides substitues par 2,3-0-isopropylidene-1-0 | |
CA2767285A1 (fr) | Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent | |
JPS587630B2 (ja) | シンキナ キナゾリンジオンユウドウタイノ セイゾウホウ | |
BE889639A (fr) | 11-alpha-amino-androstanes, leur preparation et compositions en contenant | |
MXPA01007089A (en) | Derivatives of monosaccharides as cell adhesion inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |